Lycorine Inhibits Chandipura Virus Replication In Vitro
Journal of Medical Virology · 2025-10 · 97 (10)
DOI: 10.1002/jmv.70636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 04.10.2025. Verfasst von Tanvi Agrawal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India. Hauptthemen laut MEDLINE: Amaryllidaceae Alkaloids, Virus Replication, Phenanthridines, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: The study was supported by Intramural funding from THSTI core grant, Translational Research Program (TRP) funded by Department of `Biotechnology, India..
Abstract (Originalsprache)
Chandipura virus (CHPV), a neurotropic member of the Rhabdoviridae family, causes severe paediatric encephalitis outbreaks in India with high fatality rates and no approved antiviral therapies. In this study, lycorine, a plant‐derived alkaloid with established broad‐spectrum antiviral activity, was evaluated for its efficacy against CHPV. In vitro treatment with lycorine resulted in a > 2.5 log₁₀ reduction in viral, with minimal cytotoxicity and favourable selectivity indices across multiple cell lines. Time‐of‐addition assays demonstrated that lycorine exerts its antiviral effect during early stages of infection, without affecting the viral entry or egress. Quantitative RT‐PCR revealed a significant inhibition of CHPV positive‐strand RNA synthesis, indicating disruption of early replication steps. To elucidate the mechanism of action, molecular docking studies were performed using a structural model of CHPV L protein, based on high‐homology alignment with Vesicular Stomatitis Virus (VSV) polymerase. Docking and free energy calculations identified two high‐affinity lycorine‐binding sites within the RdRp catalytic domain, stabilized by hydrogen bonding and aromatic interactions. These findings suggest that lycorine may inhibit CHPV replication by targeting the viral RNA‐dependent RNA polymerase. Overall, this study highlights lycorine as a promising antiviral candidate against CHPV and potentially other neurotropic RNA viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India.
- Centre for Virus Research, Therapeutics and Vaccines, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India.
- Centre for Tuberculosis Research, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India.
ORCID-Profile: Tanvi Agrawal, Amit Awasthi
Förderung
- The study was supported by Intramural funding from THSTI core grant, Translational Research Program (TRP) funded by Department of `Biotechnology, India.
Zitieren
APA
Agrawal, T., Singh, S., Kaur, G., Rathore, S., Sharma, H., Rajput, G., Samal, S., & Awasthi, A. (2025). Lycorine Inhibits Chandipura Virus Replication In Vitro. Journal of Medical Virology, 97(10). https://doi.org/10.1002/jmv.70636
Vancouver
Agrawal T, Singh S, Kaur G, Rathore S, Sharma H, Rajput G, et al. Lycorine Inhibits Chandipura Virus Replication In Vitro. Journal of Medical Virology. 2025;97(10). doi:10.1002/jmv.70636
BibTeX
@article{Agrawal2025,
author = {Agrawal, Tanvi and Singh, Shikha and Kaur, Gurleen and Rathore, Shiva and Sharma, Harshita and Rajput, Gunjan and Samal, Sweety and Awasthi, Amit},
title = {Lycorine Inhibits Chandipura Virus Replication In Vitro},
journal = {Journal of Medical Virology},
year = {2025},
volume = {97},
number = {10},
doi = {10.1002/jmv.70636}
}
EUVIMED